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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. The involvement of reactive oxygen species in various diseases
has been demonstrated almost in vitro or in animal studies and
clinical studies supporting the involvement of reactive oxygen
species are very few. Bilirubin has been recognized as an important
antioxidant and also shown to have an inhibitory effect on the
activity of NADPH oxidase, which may be an important source for
superoxide production in various tissues. When the prevalence of
vascular complcations was compared in diabetic patients with and
without a congenital hyperbilirubinemia (Gilbert syndrome), the
prevalence of retinopathy, macroalbuminuria and coronary artery
disease in patients with Gilbert syndrome was about 20% of that
in those without Gilbert syndrome. For study of lifestyle related
diseases, the Fukuoka Cohort was constructed from 2003 to 2009
in Kyushu area in Japan, which contains a total of 12,949 persons.
Cross sectional study of the Fukuoka Cohort revealed an inverse
relation between serum bilirubin level and the prevalence of type
2 diabetes mellitus. A precursor of bilirubin, biliverdin treated
db/db mice exhibited less albuminuria and nephropathic changes.
These effects were paralleled with normalization of oxidative
stress markers and expression of NAD(P)H oxidase subunits in
kidney. These results suggested that oxidative stress is an exacer 
bating factor of type 2 diabetes mellitus and that antioxidant
therapies are of value to diabetic nephropathy.
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Introduction It has been shown that reactive oxygen species (ROS) are
involved in the development of lifestyle-related diseases such
as atherosclerosis, myocardial infarction, cerebrovascular disease,
diabetes mellitus, cancer, and even osteoporosis. However, the
involvement of oxidative stress in various diseases has been
demonstrated almost in vitro or in animal studies and direct
clinical studies supporting the involvement of ROS are very few.
In clinical studies, the participation of ROS has been suggested
indirectly, for instance, an antagonist of type 1 angiotensin II
receptor (angiotensin receptor blocker: ARB) was shown not only
to improve hypertension but also to decrease incidence of diabetes
of mellitus in large-scale clinical trials. Suppression of diabetes
mellitus is thought to be due to repression of insulin resistance
by ARB, however, angiotensin II has been suggested to promote
ROS production in vitro. On the other hand, negative data
about the participation of ROS in lifestyle-related diseases were
recently reported in a randomized, double-blind, placebo-controlled
factorial long-term trial of vitamin E and vitamin C, in which
neither vitamin E nor vitamin C supplementation reduced the
risk of major cardiovascular events.(1) Diabetes mellitus leads to
microvascular complications such as retinopathy, nephropathy
and neuropathy, but also is an important independent risk factor
for cardiovascular disease. Several well-researched theories have
been proposed to explain how chronic hyperglycemia or post-
prandial hyperglycemia causes the micro- or macro-vascular
derangements. These theories include increased polyol pathway
flux, increased advanced glycation end-product (AGE) forma-
tion,(2) activation of protein kinase C (PKC)(3) and increased oxida-
tive stress.(4) Recent reports including ours have shown that a
PKC-dependent activation of NAD(P)H oxiadse (NOX) may be a
major source of increased oxidative stress in vascular tissues of
diabetes.(5–10) Oxidative stress also has been paid increasing
attention to as a common underlying mechanism for progressive
β-cell dysfunction as well as diabetic vascular complications.(11)
Bilirubin has been recognized as an important antioxidant(12)
and also shown to have an inhibitory effect on the activity of
NOX.(13,14) Higher concentrations of serum bilirubin were related
to decreased risk of coronary artery disease(15–18) and stroke.(19) In
this article, we propose the strong involvement of ROS in the
development of type 2 diabetes mellitus and its complications by
presenting clinical and experimental animal model data about
analysis of relationship between hyperbilirubinemia and diabetes
mellitus.
Gilbert Syndrome and Prevalence of Diabetic Vascular
Complications
We compared the prevalence of vascular complications in
diabetic patients with and without Gilbert syndrome (GS), a
congenital hyperbilirubinemia. Screening of 5,080 diabetic patients
who visited Kyushu University Hospital and 12 other hospitals
and clinics in the Kyushu District of Japan from April to June
2006 yielded 96 consecutive patients with GS, all of whom
were enrolled. Determination of GS was based on the presence
of unconjugated bilirubin-dominant hyperbilirubinemia (serum
bilirubin level >1.2 mg/dl) for 3 or more months, in the absence
of hemolytic disease and/or hepatic dysfunction. Patients with
diabetes for less than 5 years were excluded. For vascular out-
comes, retinopathy was assessed by funduscopic examination;
macroalbuminuria was defined as urinary albumin to creatinine
ratio of  >300 mg/g; coronary artery disease was defined as a history
of acute myocardial infarction, angina confirmed by clinically
significant obstruction on coronary angiography, or revasculariza-
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tion; cerebrovascular disease was defined as a history of symp-
tomatic stroke, confirmed by brain imaging. Metabolic variables
and the prevalence of vascular complications were compared to
those of 426 diabetic patients without GS who visited Kyushu
University Hospital during the same period. Serum bilirubin
levels were approximately 2.5-fold higher in patients with GS.
The adjusted odds ratio for the association of GS with retinopathy,
macroalbuminuria or coronary artery disease was 0.20–0.22
(Table 1), suggesting that sustained hyperbilirubinemia can reduce
diabetic complications by almost 80% by its antioxidant action
and an inhibitory effect on NOX.(20)
Serum Bilirubin Level and Type 2 Diabetes Mellitus in
Middle Aged and Elderly Japanese Men and Women
Bilirubin, high sensitivity C reactive protein (hs CRP)
and glycated hemoglobin. The study subjects were partici-
pants in the baseline survey of the Kyushu University Fukuoka
Cohort Study. Residents aged 49 to 76 years in the East Ward of
Fukuoka City were invited to participate in the study by mail.
During the period between February 2004 and August 2007, a
total of 12,949 persons participated in the survey. A total of 531
subjects were excluded for the following reasons: current medical
care for chronic hepatitis, liver cirrhosis or liver cancer (n = 233),
a prior history of liver cancer (n = 3), aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) greater than 3-fold of
the upper limit of the normal range, i.e., >120 U/L (n = 285),
total bilirubin >3.0 mg/dl (n = 3), serum CRP >10 mg/L (n = 212),
or serum creatinine >2.0 mg/dl (n = 44). Additionally, 12 persons
were excluded because of missing values for liver enzymes
(n = 4), creatinine (n = 6), alcohol use (n = 4), and leisure-time
physical activity (n = 1). Of the remaining 12,400 subjects, 624
under medication for diabetes mellitus were excluded in the
analysis on hs-CRP and hemoglobin A1c (HbA1c), but were
included in the analysis on prevalent diabetes. Age-adjusted
geometric means of hs-CRP were progressively lower in both
men and women with higher values of total bilirubin. p values for
trends of inverse associations were extremely small without and
with adjustment for behavioral factors and liver enzymes (Fig. 1).
Bilirubin concentrations also showed highly statistically signifi-
cant, inverse associations with HbA1c concentrations in men
and women, regardless of adjustment for the behavioral covariates
and liver enzyme activities (Fig. 2). The inverse association of
HbA1c with total bilirubin was still significant after adjustment
Table 1. Adjusted odds ratio for retinopathy, macroalbuminuria, coronary artery disease and cerebrovascular disease in
diabetic patients with Gilbert syndrome compared with those without it.
In stepwise logistic regression analysis, the prevalence of retinopathy was significantly associated with Gilbert syndrome
(GS), duration of diabetes, HbA1c; the prevalence of macroalbumiuria was associated with GS, duration of diabetes,
triglyceride; the prevalence of coronary artery disease was associated with GS, duration of diabetes, systolic blood pressure;
the prevalence of cerebrovascular disease was associated with age, triglyceride, but not GS. Odds ratio for retinopathy,
macroalbuminuria, coronary artery disease and cerebrovascular disease was adjusted for significantly determinant
variables, respectively. Reproduced from (20) with permission.
Vascular complications Odds ratio 95% C.I. χ2 value p value
Retinopathy 0.216 0.104–0.446 17.06 <0.0001
Macroalbuminuria 0.205 0.061–0.687 6.60 0.0102
Coronary artery disease 0.206 0.048–0.885 4.51 0.0336
Cerebrovascular disease 0.502 0.200–1.843 0.77 0.2172
Fig. 1. Geometric means of serum high sensitivity C reactive protein according to serum total bilirubin concentrations in men and women.
Adjusted for age (continuous variable), smoking (never, past, and current with a consumption of <20 or ≥20 cigarettes per day), alcohol use (never,
former and current with a consumption of <30, 30–59 or 60 ml of alcohol per day), body mass index (<22.5, 22.5–24.9, 25.0–27.4, and ≥27.5 kg/m2),
job related and leisure time physical activity (each categorized at quartiles), serum alanine aminotransferase (<40, 40–80, and >80 U/L), and serum
gamma glutamyltransferase (categorized at sex specific quartiles). Reproduced from (22) with permission.doi: 10.3164/jcbn.11 014FR
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for hs-CRP (p = 0.0004 for men and p<10−5 for women). Like-
wise, unconjugated bilirubin concentrations were associated
inversely with hs-CRP and HbA1c.
Bilirubin and prevalent diabetes mellitus. Prevalent cases
of type 2 diabetes numbered 907 (602 men and 305 women). The
sex- and age-adjusted odds ratios of diabetes decreased almost
progressively with increasing concentrations of total bilirubin,
showing a statistically highly significant trend. With adjustment
for the behavioral factors and liver enzymes, the association was
somewhat attenuated. Decreased odds ratios of almost the same
magnitude were noted in the three categories of total bilirubin
≥0.5 mg/dl. Further attenuation of the association occurred with
additional adjustment for hs-CRP, but the trend remained statisti-
cally significant (Table 2). The analysis was repeated for un-
conjugated and conjugated bilirubin, and the associations were
similar to those observed for total bilirubin. Pancreatic islet is
particularly susceptible to damage by oxidative stress because of
the lowest levels of intrinsic anti-oxidant defenses.(21) These data
suggested that higher concentrations of bilirubin may suppress the
development of type 2 diabetes through its anti-oxidative effect.(22)
Hyperbilirubinemic Rats and Diabetic Copmplications
Hyperbilirubinemic Gunn rats. Hereditary hyperbilirubin-
emic homologous Gunn j/j rats and age-matched control heterozy-
gous Gunn rats j/+ rats were induced to diabetes by intraperitoneal
injection of streptozotocin. At 8 weeks after the onset of diabetes,
the total serum bilirubin levels were 0.15 ± 0.02 and 0.18 ±
0.04 mg/dl in diabetic and non-diabetic Gunn j/+ rats, respec-
tively, and 7.01 ± 0.43 and 9.47 ± 0.04 mg/dl in diabetic and
non-diabetic Gunn j/j rats, respectively. Diabetic Gunn j/+ rats
exhibited marked increases in the amounts of urinary albumin
excretion compared with non-diabetic Gunn j/+ rats at 8 weeks
after the onset of diabetes, whereas diabetic Gunn j/j rats exhibited
significantly less urinary albumin excretion than diabetic Gunn
j/+ rats (Fig. 3). Urinary excretion levels of a systemic oxidative
stress marker, 8-hydroxy-2'-deoxyguanosine (8-OHdG), were
significantly higher in diabetic Gunn j/+ rats than in non-diabetic
Gunn j/+ rats at 8 weeks. The diabetes-induced increases in 8-
OHdG at 8 weeks were completely prevented in diabetic hyper-
bilirubinemic Gunn j/j rats (Fig. 4A). Immunostaining analysis
of 8-OHdG in renal tissues revealed that the staining intensities
in diabetic Gunn j/+ rats were significantly higher than those in
control Gunn j/+ rats, in both glomeruli and tubules at 24 weeks.
These increases in 8-OHdG staining intensities in glomeruli and
tubules were completely prevented in diabetic Gunn j/j rats.
Furthermore, we examined the expression of renal NOX compo-
nents by immunostaining analysis. The staining intensities for
NOX4 protein were stronger in the renal glomeruli and tubules of
diabetic Gunn j/+ rats than in those of control Gunn j/+ rats.
Western blotting analysis confirmed that the protein levels for
NOX4 were significantly increased in the kidneys of diabetic
Gunn j/+ rats compared with control Gunn j/+ rats. All of these
changes were completely prevented in diabetic Gunn j/j rats,
Fig. 2. Geometric means of serum glycated hemoglobin according to serum total bilirubin concentrations in men and women. Adjusted for
covariates as in the legend for Fig. 1. Reproduced from (22) with permission.
Table 2. Adjusted odds ratios of prevalent diabetes mellitus according to serum total bilirubin.
Odds ratios (OR) were adjusted for sex, age, smoking, alcohol use, body mass index, job related and leisure time physical activity, alanine
aminotransferase, and gamma glutamyltransferase. P for trend based on regression coefficient for a variable with ordinal values assigned to
bilirubin categories was 0.002. p for trend for OR adjusted only for sex and age was 0.00003 and that for OR adjusted further for C reactive protein
was 0.01. Reproduced from (22) with permission.
Total bilirubin concentration 
(mg/dl) ≤0.3 0.4 0.5 0.6 ≥0.7
Number of subjects 2,141 2,897 2,693 2,957 1,712
Number of prevalent cases (%) 171 (8.0) 232 (8.0) 170 (6.3) 216 (7.3) 118 (6.9)
Adjusted OR (95% C.I.) 1.00 (referent) 1.00 (0.81–1.24) 0.73 (0.58–0.91) 0.80 (0.64–1.00) 0.73 (0.56–0.94) J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 75
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Fig. 3. Urinary albumin/creatinine (Ur Alb/Cr) ratio (mg/g creatinine) in homozygous j/j (n = 10) and heterozygous j/+ Gunn rats (n = 10) at 8 weeks
after the onset of diabetes, and effect of biliverdin treatment for 12 weeks on Ur Alb/Cr ratio in db/+ mice (n = 8) and db/db mice (n = 8). A 24 h
urine sample was collected using metabolic cages. DM: streptozotocin induced diabetic, Contr: non diabetic, BVD: biliverdin treated mice. Results
are expressed as means ± SE. *: p<0.05, **: p<0.01, ***: p<0.001. Reproduced from (23) with permission.
Fig. 4. A: Urinary 8 OHdG excretion (μg/g creatinine) in homozygous j/j (n = 10) and heterozygous j/+ (n = 10) Gunn rats at 8 weeks after the onset
of diabetes. B: The effect of biliverdin treatment for 12 weeks on urinary 8 OHdG excretion (for all groups, n = 8). Results are expressed as
means ± SE. *: p<0.05, **: p<0.01, ***: p<0.001. Reproduced from (23) with permission.doi: 10.3164/jcbn.11 014FR
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which showed levels comparable to those in control Gunn j/+
rats (Fig. 5A). We investigated the effect of hyperbilirubinemia
on mesangial expansion at 24 weeks after the onset of diabetes.
The glomerular structure in diabetic Gunn j/+ rats showed
accelerated mesangial expansion compared with that observed in
control Gunn j/+ rats. The PAS-positive and nuclei-free mesangial
area was markedly increased in the glomeruli of diabetic Gunn
j/+ rats. Diabetic Gunn j/j rats showed complete prevention of
mesangial expansion.
Biliverdin administered db/db mice. A rodent model of
type 2 diabetes, db/db mice, were fed with powder diet supple-
mented with or without biliverdin (5 mg/kg) at 12 weeks of age.
Biliverdin administration orally for 2 weeks and 12 weeks did
not significantly affect body weights or blood glucose levels.
Oral administration of this dose of biliverdin did not induce a
significant elevation in serum bilirubin levels, although an intra-
peritoneal injection of the same dose induced a slight elevation in
serum bilirubin levels at 0.5 h, with rapid return to the basal levels
at 6 h after injection. Urinary albumin excretion significantly
increased in non-treated db/db mice as compared with control
db/+ mice at 2 weeks and 12 weeks after the start of biliverdin
administration. Biliverdin administration significantly attenuated
such increases in urinary albumin excretion in db/db mice (Fig. 3).
Urinary 8-OHdG excretion was significantly higher in db/db
mice than in control db/+ mice. Biliverdin administration reduced
these markers in db/db mice to control levels (Fig. 4B). The
protein levels of NOX4 were also significantly increased in renal
tissues of db/db mice. Biliverdin administration normalized all of
these changes in db/db mice to the control levels (Fig. 5B). We
also confirmed the effect of biliverdin to intracellular production
of superoxide in the renal tissues by dihydroethidium stain. The
oxidized dihydroethidium signals were significantly higher in
db/db mice than those in control mice at 12 weeks. Biliverdin
administration completely normalized oxidized dihydroethidium
(DHE) signals to the control levels. Mesangial expansion was
found in db/db mice at the age of 24 weeks, which was completely
prevented by biliverdin administration. The effect of bilirubin and
biliverdin on NOX activities in cultured human mesangial cells
were evaluated by the lucigenin method. Pretreatment of the cells
with both bilirubin and biliverdin for 24 h reduced NOX activities
in a dose-dependent manner.
Gunn rats, which exhibit a marked elevation of plasma unconju-
gated biliverdin levels due to a genetic deficiency of uridine
diphosphate glucuronosyl transferase-1 (UDPGT-1). The present
study showed that diabetic hyperbilirubinemic Gunn j/j rats
exhibited significantly less urinary albumin excretion than diabetic
non-hyperbilirubinemic Gunn j/+ rats. In addition, diabetic Gunn
j/j rats did not develop renal mesangial expansion, which is one of
the most striking morphological features of diabetic nephropathy,
6 months after the onset of diabetes, whereas diabetic Gunn j/+
rats developed typical mesangial expansion.(23) These findings
suggested that hyperbilirubinemic Gunn j/j rats were resistant to
the progression of functional and morphological features of
nephropathy after the onset of diabetes. Administration of
biliverdin (5 mg/kg) protected against both albuminuria and renal
mesangial expansion in db/db mice. Since serum biliverdin enters
cells rapidly and is converted to bilirubin by biliverdin reductase,
it is likely that the beneficial effect of biliverdin administration
may be due to increased levels of intracellular bilirubin levels
generated from exogenously administered biliverdin, rather than
increased levels of serum bilirubin or biliverdin.
The present study suggested that the mechanism underlying
these beneficial effects of hyperbilirubinemia and biliverdin
administration may be the inhibition of oxidative stress, evaluated
by systemic oxidative stress markers. The present study revealed
that biliverdin administration induced down-regulation of NOX
components in diabetic kidneys, glomeruli and human mesangium
cells. Although the nature of the sources of ROS overproduction in
diabetes has not been precisely defined, we and other investigators
have indicated that non-phagocytic NOX may be the major
sources of increased ROS production in the vascular tissues of
diabetic animals and patients, and that high glucose levels
stimulate superoxide production from vascular endothelial cells
and smooth muscle cells via a PKC-dependent activation of
NOX.(5–7,9) The non-phagocytic NOX comprises of a membrane-
associated cytchrome b558 composed of NOX family proteins
(gp91phox, NOX1, NOX4) and p22phox, and several cytosolic
regulatory components, p47phox, p67phox and Rac 1 or Rac 2.(24)
The isoform NOX4 was cloned from the kidney, where it was
found to be highly expressed.(25,26) It has been suggested that
NOX4, as a major source of ROS production in the kidney, could
have a role under pathological conditions. We previously reported
that increased expression of NOX4 may play an important role
in increased ROS production in the kidneys of streptozotocin-
induced diabetic rats.(10,27,28) The present results suggest that
down-regulation of NOX components, especially NOX4, by
Fig. 5. Western blot analysis of NOX4 protein levels in renal tissues of Gunn rats A and db mice B. NOX4 levels were normalized to the level of
β actin, and the results are expressed as the mean percentages of the levels in non treated control rats. Results are expressed as means ± SE.
**: p<0.01, ***: p<0.001. Reproduced from (23) with permission. J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 77
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hyperbilirubinemia and biliverdin administration may play an
important role in the inhibition of oxidative stress in the kidneys
of diabetic rodents.
In conclusion, we showed using bilirubin as a tool that oxidative
stress is an exacerbating factor of type 2 diabetes mellitus and
propose that antioxidant therapies are of value to diabetic
nephropathy.
Abbreviations
ROS reactive oxygen species
ARB angiotensin receptor blocker
AGE advanced glycation end-product
PKC protein kinase C
NOX NAD(P)H oxiadse
GS Gilbert syndrome
AST aspartate aminotransferase
ALT alanine aminotransferase
hs-CRP high sensitivity C-reactive protein
HbA1c hemoglobin A1c
8-OHdG 8-hydroxy-2'-deoxyguanosine
DHE dihydroethidium
UDPGT-1 uridine diphosphate glucuronosyl transferase-1
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